These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397 [TBL] [Abstract][Full Text] [Related]
5. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update. Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989 [TBL] [Abstract][Full Text] [Related]
6. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan. Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080 [TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
8. LCZ696 : a new paradigm for the treatment of heart failure? Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387 [TBL] [Abstract][Full Text] [Related]
9. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. McMurray J; Packer M; Desai A; Gong J; Greenlaw N; Lefkowitz M; Rizkala A; Shi V; Rouleau J; Solomon S; Swedberg K; Zile MR; Andersen K; Arango JL; Arnold M; Bĕlohlávek J; Böhm M; Boytsov S; Burgess L; Cabrera W; Chen CH; Erglis A; Fu M; Gomez E; Gonzalez A; Hagege AA; Katova T; Kiatchoosakun S; Kim KS; Bayram E; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires F; Refsgaard J; Senni M; Sibulo AS; Silva-Cardoso J; Squire I; Starling RC; Vinereanu D; Teerlink JR; Wong R; Eur Heart J; 2015 Feb; 36(7):434-9. PubMed ID: 25416329 [TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan (LCZ696) for the treatment of heart failure. Gori M; Senni M Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078 [TBL] [Abstract][Full Text] [Related]
11. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447 [TBL] [Abstract][Full Text] [Related]
12. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Kario K Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807 [TBL] [Abstract][Full Text] [Related]
13. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Macdonald PS Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501 [TBL] [Abstract][Full Text] [Related]
14. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
15. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block? Pham AQ; Patel Y; Gallagher B J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789 [TBL] [Abstract][Full Text] [Related]
16. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent. Sible AM; Nawarskas JJ; Alajajian D; Anderson JR Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333 [TBL] [Abstract][Full Text] [Related]
17. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Lillyblad MP Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499 [TBL] [Abstract][Full Text] [Related]
18. [The new drug is much more effective than ACE inhibitors in chronic heart failure]. Widimský J Vnitr Lek; 2015 Feb; 61(2):129-33. PubMed ID: 25813256 [TBL] [Abstract][Full Text] [Related]
19. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy. Hsiao R; Greenberg B Curr Heart Fail Rep; 2016 Aug; 13(4):172-80. PubMed ID: 27271564 [TBL] [Abstract][Full Text] [Related]
20. [Neprilysin inhibition and chronic kidney disease]. Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]